Bioventus Statistics
Share Statistics
Bioventus has 65.37M shares outstanding. The number of shares has increased by 3.14% in one year.
| Shares Outstanding | 65.37M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.28% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 44.70M |
| Failed to Deliver (FTD) Shares | 2.24K |
| FTD / Avg. Volume | 0.58% |
Short Selling Information
The latest short interest is 975.98K, so 1.49% of the outstanding shares have been sold short.
| Short Interest | 975.98K |
| Short % of Shares Out | 1.49% |
| Short % of Float | 2.18% |
| Short Ratio (days to cover) | 3.04 |
Valuation Ratios
The PE ratio is -2.11 and the forward PE ratio is 17.94.
| PE Ratio | -2.11 |
| Forward PE | 17.94 |
| PS Ratio | 0.64 |
| Forward PS | 1.1 |
| PB Ratio | 1.9 |
| P/FCF Ratio | 41.36 |
| PEG Ratio | n/a |
Enterprise Valuation
Bioventus Inc. has an Enterprise Value (EV) of 702.66M.
| EV / Earnings | -4.5 |
| EV / Sales | 1.37 |
| EV / EBITDA | -30.46 |
| EV / EBIT | -8.6 |
| EV / FCF | 88.03 |
Financial Position
The company has a current ratio of 1.53, with a Debt / Equity ratio of 2.27.
| Current Ratio | 1.53 |
| Quick Ratio | 1.01 |
| Debt / Equity | 2.27 |
| Total Debt / Capitalization | 69.46 |
| Cash Flow / Debt | 0.04 |
| Interest Coverage | -2.01 |
Financial Efficiency
Return on equity (ROE) is -0.9% and return on capital (ROIC) is -13.28%.
| Return on Equity (ROE) | -0.9% |
| Return on Assets (ROA) | -0.19% |
| Return on Capital (ROIC) | -13.28% |
| Revenue Per Employee | 497.42K |
| Profits Per Employee | -151.68K |
| Employee Count | 1.03K |
| Asset Turnover | 0.63 |
| Inventory Turnover | 2.02 |
Taxes
| Income Tax | 85.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 111.34% in the last 52 weeks. The beta is 0.88, so Bioventus 's price volatility has been higher than the market average.
| Beta | 0.88 |
| 52-Week Price Change | 111.34% |
| 50-Day Moving Average | 11.68 |
| 200-Day Moving Average | 8.57 |
| Relative Strength Index (RSI) | 39.24 |
| Average Volume (20 Days) | 383.85K |
Income Statement
In the last 12 months, Bioventus had revenue of 512.35M and earned -156.23M in profits. Earnings per share was -2.49.
| Revenue | 512.35M |
| Gross Profit | 328.19M |
| Operating Income | -81.72M |
| Net Income | -156.23M |
| EBITDA | -23.07M |
| EBIT | -81.72M |
| Earnings Per Share (EPS) | -2.49 |
Balance Sheet
The company has 36.96M in cash and 394.85M in debt, giving a net cash position of -357.88M.
| Cash & Cash Equivalents | 36.96M |
| Total Debt | 394.85M |
| Net Cash | -357.88M |
| Retained Earnings | -321.54M |
| Total Assets | 769.49M |
| Working Capital | 87.20M |
Cash Flow
In the last 12 months, operating cash flow was 15.34M and capital expenditures -7.36M, giving a free cash flow of 7.98M.
| Operating Cash Flow | 15.34M |
| Capital Expenditures | -7.36M |
| Free Cash Flow | 7.98M |
| FCF Per Share | 0.13 |
Margins
Gross margin is 6.41K%, with operating and profit margins of -1.59K% and -3.05K%.
| Gross Margin | 6.41K% |
| Operating Margin | -1.59K% |
| Pretax Margin | -2.36K% |
| Profit Margin | -3.05K% |
| EBITDA Margin | -4.5% |
| EBIT Margin | -15.95% |
| FCF Margin | 1.56% |
Dividends & Yields
BVS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -23.85% |
| FCF Yield | 1.17% |
Analyst Forecast
The average price target for BVS is $15, which is 43.7% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $15 |
| Price Target Difference | 43.7% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | 0.86 |
| Piotroski F-Score | 5 |